Biomanufacturing Pioneer Cauldron Raises $13.25M and Earns Spot on Fast Company’s Most Innovative Companies List

Funding led by Main Sequence Ventures will expand Cauldron’s continuous “hyper-fermentation” technology to deliver lower-cost, industrial-scale bio-production.

ORANGE, Australia--(BUSINESS WIRE)--Cauldron Ferm, a leader in advanced biomanufacturing, today announced a $13.25 million Series A2 priced round and its inclusion on Fast Company’s 2026 list of the World’s Most Innovative Companies. The round was led by Main Sequence Ventures, with participation from Horizons Ventures, SOSV, and NGS Super, bringing Cauldron’s total funding to $26 million.

The new capital and Fast Company recognition underscore growing momentum behind Cauldron’s continuous “hyper-fermentation” platform – a proprietary technology designed to deliver step-change improvements in bioprocess efficiency. Cauldron’s progress comes at a pivotal time for the broader sector, as demand for cost-competitive bio-production accelerates globally.

Biomanufacturing uses living cells as programmable factories, where bio-engineered microbes convert simple inputs like sugars into valuable products. Cauldron’s key advantage is keeping these microbes in a highly productive steady state and running processes continuously for long periods. This increases output while significantly lowering production costs, helping bioproducts compete with conventional industrial alternatives.

“For biomanufacturing to compete in industrial sectors, bioproducts have to deliver on costs, scale, and quality. Bioprocess innovation is how we get there,” said Michele Stansfield, Co-founder and CEO of Cauldron. “We’re honoured to be backed by a dedicated group of experienced investors and proud to be recognised as one of the World’s Most Innovative Companies. This milestone reflects the impact of our platform at a time when governments and corporations are urgently seeking competitive bio-based solutions to address supply chain pressure.”

Global supply chains remain fragile, with 80% of organizations reporting supply chain disruptions in 2024 – a challenge Cauldron’s continuous production model is designed to address. Estimates suggest up to 60% of the physical inputs to the global economy could be produced biologically, fundamentally reshaping how essential products are sourced and secured. Cauldron’s technology makes this vision commercially viable by enabling production of critical inputs across industries at the costs and volumes required for mainstream adoption.

Cauldron has demonstrated the impact of hyper-fermentation for clients commercializing bio-based food ingredients, chemicals, and nutraceuticals. The company is the first to demonstrate true industrial-scale continuous fermentation for synthetic biology strains at 10,000-liter scale.

“NGS Super backed Cauldron because we see advanced biomanufacturing as a powerful secular trend reshaping how critical inputs are produced, driven by supply chain resilience, decarbonisation, and the need for cost competitive alternatives to traditional industrial processes,” said Ben Squires, Chief Investment Officer at NGS Super, one of the largest pension funds in Australia. “Cauldron’s continuous ‘hyper-fermentation’ platform is focused on the key constraint in the sector: improving productivity and unit economics at industrial scale. That combination of technology differentiation and real-world commercial validation is why we decided to invest.”

The new capital will enable Cauldron to meet growing demand from governments and corporations investing in biomanufacturing infrastructure. To accelerate scale up of Cauldron’s technology for commercial production, the company is working with corporate partners to evaluate retrofitting existing facilities to deploy hyper-fermentation at partner sites. Cauldron has also secured non-dilutive government grants in Australia and the U.S. to support expansion of Cauldron’s demo-scale operations in Orange, NSW and planning for industrial-scale production.

“Cauldron is proving that biology can run continuously, predictably, and at the volumes global supply chains demand. Hyper-fermentation closes the gap between breakthrough strains and reliable, cost-competitive production. As long-term deep tech investors – and Asia Pacific's largest dedicated deep tech venture firm – we see this as a systemic industrial transformation,” said Phil Morle, Partner at Main Sequence Ventures. “In a market distracted by AI hype cycles, we’re backing the hard, physical work of scaling biology. That’s what builds enduring companies, and it’s why we believe Cauldron is at the forefront of making bioindustrial manufacturing commercially inevitable.”

Founded in 2022, Cauldron has rapidly progressed from early validation to commercial proof points. In 2025, the World Economic Forum named Cauldron a “Technology Pioneer” for its potential to reshape manufacturing. The Series A2 funding further positions the company as a global leader in bioindustrial manufacturing and highlights demand for its advanced continuous fermentation technology.

About Cauldron Ferm

Cauldron is pioneering next-generation bioprocess innovation to accelerate industrial-scale, commercially viable biomanufacturing. Its proprietary hyper-fermentation platform enables a step-change in production efficiency, delivering higher productivity, lower costs, and reduced resource inputs with a stable continuous process at scale. Headquartered in regional Australia, Cauldron operates a 30,000-liter demonstration facility in Orange, NSW and works with partners in four countries to optimize and scale fermentation processes across sectors. Founded in 2022, Cauldron has earned global recognition for its technology impact, including selection for the World Economic Forum’s Technology Pioneers list and Fast Company’s Most Innovative Companies.